• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒 SARS-CoV-2 主蛋白酶(3CLpro)的生化和生物物理特性分析。

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2.

机构信息

Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates.

出版信息

Sci Rep. 2020 Dec 17;10(1):22200. doi: 10.1038/s41598-020-79357-0.

DOI:10.1038/s41598-020-79357-0
PMID:33335206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7747600/
Abstract

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19). An appealing antiviral drug target is the coronavirus 3C-like protease (3CLpro) that is responsible for the processing of the viral polyproteins and liberation of functional proteins essential for the maturation and infectivity of the virus. In this study, multiple thermal analytical techniques have been implemented to acquire the thermodynamic parameters of 3CLpro at different buffer conditions. 3CLpro exhibited relatively high thermodynamic stabilities over a wide pH range; however, the protease was found to be less stable in the presence of salts. Divalent metal cations reduced the thermodynamic stability of 3CLpro more than monovalent cations; however, altering the ionic strength of the buffer solution did not alter the stability of 3CLpro. Furthermore, the most stable thermal kinetic stability of 3CLpro was recorded at pH 7.5, with the highest enthalpy of activation calculated from the slope of Eyring plot. The biochemical and biophysical properties of 3CLpro explored here may improve the solubility and stability of 3CLpro for optimum conditions for the setup of an enzymatic assay for the screening of inhibitors to be used as lead candidates in the discovery of drugs and design of antiviral therapeutics against COVID-19.

摘要

严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)是引发 2019 年新型冠状病毒病(COVID-19)的病原体。冠状病毒 3C 样蛋白酶(3CLpro)是一种有吸引力的抗病毒药物靶标,该酶负责病毒多蛋白的加工以及释放成熟和感染病毒所必需的功能蛋白。在这项研究中,采用了多种热分析技术来获取不同缓冲条件下 3CLpro 的热力学参数。3CLpro 在很宽的 pH 范围内表现出相对较高的热力学稳定性;然而,研究发现蛋白酶在盐存在下稳定性降低。二价金属阳离子比单价阳离子更能降低 3CLpro 的热力学稳定性;然而,改变缓冲溶液的离子强度不会改变 3CLpro 的稳定性。此外,在 pH7.5 时记录到 3CLpro 最稳定的热动力学稳定性,最高的活化焓是从 Eyring 图的斜率计算得出的。这里探索的 3CLpro 的生化和生物物理特性可能会提高 3CLpro 的溶解度和稳定性,从而优化建立酶促测定的条件,以筛选用于发现 COVID-19 药物和设计抗病毒治疗的抑制剂的先导候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/44020bc6ac38/41598_2020_79357_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/d4dfd7f0f4d1/41598_2020_79357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/75d087c05799/41598_2020_79357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/a6b4dd7e6ec7/41598_2020_79357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/6a12b0285b30/41598_2020_79357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/44020bc6ac38/41598_2020_79357_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/d4dfd7f0f4d1/41598_2020_79357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/75d087c05799/41598_2020_79357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/a6b4dd7e6ec7/41598_2020_79357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/6a12b0285b30/41598_2020_79357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb5d/7747600/44020bc6ac38/41598_2020_79357_Fig5_HTML.jpg

相似文献

1
Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2.新型冠状病毒 SARS-CoV-2 主蛋白酶(3CLpro)的生化和生物物理特性分析。
Sci Rep. 2020 Dec 17;10(1):22200. doi: 10.1038/s41598-020-79357-0.
2
Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro.二甲基亚砜降低了主要 SARS-CoV-2 蛋白酶 3CLpro 的稳定性但增强了其催化活性。
FASEB J. 2021 Aug;35(8):e21774. doi: 10.1096/fj.202100994.
3
3-chymotrypsin-like protease in SARS-CoV-2.SARS-CoV-2 中的 3-糜蛋白酶样蛋白酶。
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20231395.
4
The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.PGG 和 EGCG 对 SARS-CoV-2 3CL 样蛋白酶的抑制作用。
Biochem Biophys Res Commun. 2022 Feb 5;591:130-136. doi: 10.1016/j.bbrc.2020.12.106. Epub 2021 Jan 6.
5
pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity.阐明 SARS-CoV-2 3-胰凝乳蛋白酶样蛋白酶(3CLpro)的 pH 曲线有助于揭示其催化机制和对活性至关重要的组氨酸残基。
J Biol Chem. 2023 Feb;299(2):102790. doi: 10.1016/j.jbc.2022.102790. Epub 2022 Dec 9.
6
Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).基于细胞的高通量筛选技术用于发现针对 SARS-CoV-2 主蛋白酶(3CLpro)的抗病毒抑制剂
Mol Biotechnol. 2021 Mar;63(3):240-248. doi: 10.1007/s12033-021-00299-7. Epub 2021 Jan 19.
7
Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.靶向冠状病毒 3C 样主蛋白酶的抗病毒候选药物概述。
FEBS J. 2021 Sep;288(17):5089-5121. doi: 10.1111/febs.15696. Epub 2021 Feb 1.
8
Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease.鉴定 SARS-CoV-2 主要蛋白酶的宿主细胞蛋白底物。
Int J Mol Sci. 2020 Dec 15;21(24):9523. doi: 10.3390/ijms21249523.
9
Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor.使用多克隆抗血清和基于荧光素酶的生物传感器检测 SARS-CoV-2 3CLpro 的表达和活性。
Virology. 2021 Apr;556:73-78. doi: 10.1016/j.virol.2021.01.010. Epub 2021 Jan 26.
10
Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity.开发一种用于检测 SARS-CoV-2 3CLpro 活性的比色分析方法。
Biochem J. 2022 Apr 29;479(8):901-920. doi: 10.1042/BCJ20220105.

引用本文的文献

1
Boosting immunity: synergistic antiviral effects of luteolin, vitamin C, magnesium and zinc against SARS-CoV-2 3CLpro.增强免疫力:木犀草素、维生素 C、镁和锌对 SARS-CoV-2 3CLpro 的协同抗病毒作用。
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20240617.
2
3-chymotrypsin-like protease in SARS-CoV-2.SARS-CoV-2 中的 3-糜蛋白酶样蛋白酶。
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20231395.
3
Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.新型冠状病毒3C样蛋白酶拟肽抑制剂的合成与生物学评价

本文引用的文献

1
Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics.SARS-CoV-2 和 HIV 靶向宿主细胞的出现和分子机制及潜在治疗方法。
Infect Genet Evol. 2020 Nov;85:104583. doi: 10.1016/j.meegid.2020.104583. Epub 2020 Oct 6.
2
Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches.蛋白酶在 COVID-19 感染中的作用和有前景的治疗方法。
Biochem Pharmacol. 2020 Dec;182:114225. doi: 10.1016/j.bcp.2020.114225. Epub 2020 Sep 19.
3
Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.
Eur J Med Chem. 2024 Mar 15;268:116263. doi: 10.1016/j.ejmech.2024.116263. Epub 2024 Feb 24.
4
Bayesian Inference Elucidates the Catalytic Competency of the SARS-CoV-2 Main Protease 3CL.贝叶斯推断阐明了 SARS-CoV-2 主要蛋白酶 3CL 的催化能力。
Anal Chem. 2023 Oct 10;95(40):14981-14989. doi: 10.1021/acs.analchem.3c02459. Epub 2023 Sep 26.
5
The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒的主要蛋白酶3CLpro:如何化敌为友。
Front Bioeng Biotechnol. 2023 Jun 29;11:1187761. doi: 10.3389/fbioe.2023.1187761. eCollection 2023.
6
Advances in research on 3C-like protease (3CL) inhibitors against SARS-CoV-2 since 2020.2020年以来针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的3C样蛋白酶(3CL)抑制剂的研究进展
RSC Med Chem. 2022 Oct 27;14(1):9-21. doi: 10.1039/d2md00344a. eCollection 2023 Jan 25.
7
A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2.一种关于设计有效RdRp抑制剂用于治疗新型冠状病毒肺炎的策略的假说。
3 Biotech. 2023 Jan;13(1):12. doi: 10.1007/s13205-022-03430-w. Epub 2022 Dec 16.
8
Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation study.将抗癌药物重新用于抑制 SARS-CoV-2 蛋白的多靶点抑制剂:从分子对接和 MD 模拟研究中获得的见解。
Microb Pathog. 2022 Aug;169:105615. doi: 10.1016/j.micpath.2022.105615. Epub 2022 Jun 8.
9
Surface cysteines could protect the SARS-CoV-2 main protease from oxidative damage.表面半胱氨酸可以保护 SARS-CoV-2 主蛋白酶免受氧化损伤。
J Inorg Biochem. 2022 Sep;234:111886. doi: 10.1016/j.jinorgbio.2022.111886. Epub 2022 Jun 2.
10
Effect of pH on stability of dimer structure of the main protease of coronavirus-2.pH 值对冠状病毒主蛋白酶二聚体结构稳定性的影响。
Biophys Chem. 2022 Aug;287:106829. doi: 10.1016/j.bpc.2022.106829. Epub 2022 May 19.
自然进化的产物(SARS、MERS 和 SARS-CoV-2);从 SARS 到 SARS-CoV-2,致命疾病。
Hum Vaccin Immunother. 2021 Jan 2;17(1):62-83. doi: 10.1080/21645515.2020.1797369. Epub 2020 Aug 12.
4
Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution.快速进化的新型冠状病毒的比较基因组分析揭示了系统发育地理分布的镶嵌模式。
mSystems. 2020 Jul 28;5(4):e00505-20. doi: 10.1128/mSystems.00505-20.
5
The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections.SARS-CoV-2 感染的自然史、病理学和临床表现。
J Neuroimmune Pharmacol. 2020 Sep;15(3):359-386. doi: 10.1007/s11481-020-09944-5. Epub 2020 Jul 21.
6
Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency.严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的演变,作为 2019 年冠状病毒病(COVID-19)大流行:全球卫生紧急事件。
Sci Total Environ. 2020 Aug 15;730:138996. doi: 10.1016/j.scitotenv.2020.138996. Epub 2020 Apr 30.
7
Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review.新型冠状病毒 SARS-CoV-2、SARS-CoV 和中东呼吸综合征冠状病毒(MERS-CoV)相关病毒性肺炎的研究:文献综述。
APMIS. 2020 Jun;128(6):423-432. doi: 10.1111/apm.13047.
8
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
9
Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).新型冠状病毒病 2019(COVID-19)的流行病学、诊断、治疗和疫苗的现状。
J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324. doi: 10.4014/jmb.2003.03011.
10
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.SARS-CoV-2 主蛋白酶的晶体结构为设计改良的 α-酮酰胺抑制剂提供了基础。
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.